Published in N Engl J Med on February 17, 1966
Pseudohyperkalaemia. Br Med J (Clin Res Ed) (1985) 1.32
Hyperkalaemia in patients in hospital. Br Med J (Clin Res Ed) (1983) 1.13
Pseudohyperkalaemia associated with hereditary spherocytosis in four members of a family. Postgrad Med J (1994) 1.09
Pseudohyperkalemia in serum: a new insight into an old phenomenon. Clin Med Res (2008) 1.06
Misleading biochemical laboratory test results. Can Med Assoc J (1984) 0.91
Rheumatoid arthritis: an unrecognised cause of pseudohyperkalaemia. BMJ (1988) 0.87
Determinants of magnitude of pseudohyperkalemia in thrombocytosis. Korean J Intern Med (1990) 0.77
Spontaneous pplenic rupture and pseudo-hyperkalaemia in chronic lymphatic leukaemia. Postgrad Med J (1976) 0.75
Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol (1982) 43.81
Report of the Committee on Hodgkin's Disease Staging Classification. Cancer Res (1971) 13.16
Aspergillosis. The spectrum of the disease in 98 patients. Medicine (Baltimore) (1970) 5.98
Combination chemotherapy in the treatment of advanced Hodgkin's disease. Ann Intern Med (1970) 5.03
Assessment of response to therapy in advanced breast cancer. Br J Cancer (1977) 3.70
Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med (1992) 3.54
Pharmacokinetic rationale for peritoneal drug administration in the treatment of ovarian cancer. Cancer Treat Rep (1978) 2.42
Hodgkin's disease. Immunologic, clinical, and histologic features of 50 untreated patients. Ann Intern Med (1967) 2.38
Ectopic production of human chorionic gonadotrophin by neoplasms. Ann Intern Med (1973) 2.30
Heart in malignant lymphoma (Hodgkin's disease, lymphosarcoma, reticulum cell sarcoma and mycosis fungoides). A study of 196 autopsy cases. Am J Cardiol (1968) 2.23
Endomyocardial disease and eosinophilia. A clinical and pathologic spectrum. Am J Med (1969) 2.13
NIH conference. T-cell lymphoproliferative syndrome associated with human T-cell leukemia/lymphoma virus. Ann Intern Med (1984) 2.10
Clinical pharmacology of cyclophosphamide. Cancer Res (1973) 2.08
Human alkaline phosphatase. Immunochemical identification of organ-specific isoenzymes. J Biol Chem (1968) 2.06
Effects of tamoxifen therapy on lipid and lipoprotein levels in postmenopausal patients with node-negative breast cancer. J Natl Cancer Inst (1990) 1.97
Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol (2001) 1.94
A computer data base for information on cancer treatment. N Engl J Med (1987) 1.92
Second malignancies complicating Hodgkin's disease in remission. Lancet (1975) 1.90
Intestinal lymphangiectasia: a protein-losing enteropathy with hypogammaglobulinemia, lymphocytopenia and impaired homograft rejection. J Clin Invest (1967) 1.88
Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. 3. Physiological and medical implications. Clin Chem (1970) 1.85
Pseudomonas pneumonia. A retrospective study of 36 cases. Am J Med (1973) 1.83
Fundamental dilemmas of the randomized clinical trial process: results of a survey of the 1,737 Eastern Cooperative Oncology Group investigators. J Clin Oncol (1994) 1.79
A randomized comparative trial of adriamycin versus methotrexate in combination drug therapy. Cancer (1978) 1.71
Combination versus single agent chemotherapy: a review of the basis for selection of drug treatment of cancer. Cancer (1975) 1.66
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. II. Pathologic correlations. Am J Med (1975) 1.65
Summary of infectious complications occurring in patients with Hodgkin's disease. Cancer Res (1966) 1.62
Recovery of cytomegalovirus from adults with neoplastic disease. Ann Intern Med (1966) 1.58
Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. II. Estimating biological components of variation. Clin Chem (1970) 1.55
Twenty years of MOPP therapy for Hodgkin's disease. J Clin Oncol (1986) 1.55
Second malignant neoplasms complicating Hodgkin's disease: the National Cancer Institute experience. J Clin Oncol (1984) 1.55
The consequences of the chemotherapy of Hodgkin's disease: The 10th David A. Karnofsky Memorial Lecture. Cancer (1981) 1.52
Advanced ovarian adenocarcinoma. A prospective clinical trial of melphalan (L-PAM) versus combination chemotherapy. N Engl J Med (1978) 1.52
Extrapulmonary small-cell carcinoma. A review of the literature with emphasis on therapy and outcome. Medicine (Baltimore) (1987) 1.50
Advanced diffuse histiocytic lymphoma, a potentially curable disease. Lancet (1975) 1.49
Delayed hypersensitivity in Hodgkin's disease. A study of 103 untreated patients. Am J Med (1972) 1.49
A decade of combination chemotherapy of advanced Hodgkin's disease. Cancer (1972) 1.46
The use of drugs in combination for the treatment of cancer: rationale and results. N Engl J Med (1973) 1.43
A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst (1976) 1.42
Randomized comparison of three adriamycin regimens for metastatic soft tissue sarcomas. J Clin Oncol (1987) 1.42
Nonlymphomatous malignant tumors complicating Hodgkin's disease. Possible association with intensive therapy. N Engl J Med (1972) 1.40
Report of the Committee on Hodgkin's Disease Staging Procedures. Cancer Res (1971) 1.38
Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med (1980) 1.37
Infection in lymphoma. Histology, treatment, and duration in relation to incidence and survival. JAMA (1966) 1.34
Cancer treatment and age: patient perspectives. J Natl Cancer Inst (1993) 1.34
Osteonecrosis of the femoral head in patients with lymphoma treated with intermittent combination chemotherapy (including corticosteroids). Cancer (1975) 1.33
Special report. Steriod receptors in breast cancer. N Engl J Med (1979) 1.33
Combination chemotherapy for advanced breast cancer: response and effect on survival. Ann Intern Med (1976) 1.33
Malignant lymphoma. 1. The histology and staging of 473 patients at the National Cancer Institute. Cancer (1982) 1.32
Enhancement of the antitumor effects of 1,3-bis(2-chloroethyl)-1-nitrosourea and cyclophosphamide by vitamin A. J Natl Cancer Inst (1972) 1.32
Treatment of Burkitt's tumor with cyclophosphamide. Cancer (1970) 1.29
L-asparaginase: therapeutic and toxic effects in patients with neoplastic disease. N Engl J Med (1969) 1.29
Prolonged disease-free survival in Hodgkin's disease with MOPP reinduction after first relapse. Ann Intern Med (1979) 1.28
In vitro growth of normal and leukemic human bone marrow. J Natl Cancer Inst (1971) 1.27
Clinical implications of cytogenetic variants in chronic myelocytic leukemia (CML). Blood (1968) 1.26
Elevated antibody titers to Epstein-Barr virus in Hodgkin's disease. Cancer (1971) 1.25
Increased permeability of human erythrocytes induced by amphotericin B. J Infect Dis (1971) 1.25
Plasmacytic myeloma. A study of the relationship of survival to various clinical manifestations and anomalous protein type in 112 patients. Am J Med (1967) 1.25
Diffuse aggressive lymphomas: increased survival after alternating flexible sequences of proMACE and MOPP chemotherapy. Ann Intern Med (1983) 1.23
Sequential nonsurgical and surgical staging of non-Hodgkin's lymphoma. Ann Intern Med (1976) 1.22
Central nervous system complications in patients with diffuse histiocytic and undifferentiated lymphoma: leukemia revisited. Blood (1976) 1.22
The calculation of actual or received dose intensity: a comparison of published methods. J Clin Oncol (1991) 1.21
Biological and analytic components of variation in long-term studies of serum constituents in normal subjects. IV. Results of a study designed to eliminate long-term analytic deviations. Clin Chem (1971) 1.21
Phase I and pharmacological studies of 5-fluorouracil administered intraperitoneally. Cancer Res (1980) 1.20
Pneumocystis carinii: the spectrum of diffuse interstitial pneumonia in patients with neoplastic diseases. Ann Intern Med (1970) 1.19
Pentamidine: clinical pharmacologic correlations in man and mice. Clin Pharmacol Ther (1970) 1.19
Non-Hodgkin's lymphomas in leukemic phase: clinicopathologic correlations. Am J Med (1980) 1.19
Central nervous system involvement in Burkitt's lymphoma. Blood (1970) 1.16
Management of patients with malignant lymphoma: a comparative study with cyclophosphamide and vinca alkaloids. Cancer Res (1968) 1.16
Long-term follow up of ovarian function in women treated with MOPP chemotherapy for Hodgkin's disease. Am J Med (1981) 1.16
Resolution of longstanding protein-losing enteropathy in a patient with intestinal lymphangiectasia after treatment for malignant lymphoma. Gastroenterology (1981) 1.16
Percutaneous liver biopsy, peritoneoscopy and laparotomy: an assessment of relative merits in the lymphomata. Br J Cancer Suppl (1975) 1.15
The health consequences of smoking. Cancer. Med Clin North Am (1992) 1.15
American Burkitt's lymphoma: a clinicopathologic study of 30 cases. I. Clinical factors relating to prolonged survival. Am J Med (1975) 1.15
The American Burkitt Lymphoma Registry: a progress report. Ann Intern Med (1975) 1.14
Clinical trials and drug toxicity in the elderly. The experience of the Eastern Cooperative Oncology Group. Cancer (1983) 1.14
Hematologic and cytogenetic remission of blastic transformation in chronic granulocytic leukemia. Blood (1971) 1.14
The treatment of indolent lymphomas: watchful waiting v aggressive combined modality treatment. Semin Hematol (1988) 1.14
Central nervous system complications of non-Hodgkin's lymphoma. The potential role for prophylactic therapy. Am J Med (1979) 1.13
Conventional-dose salvage combination chemotherapy in patients relapsing with Hodgkin's disease after combination chemotherapy: the low probability for cure. J Clin Oncol (1992) 1.13
Diffuse histiocytic lymphoma involving the gastrointestinal tract. Cancer (1978) 1.13
Assessment of response to therapy in advanced breast cancer. A project of the programme on clinical oncology of the International Union against Cancer, Geneva, Switzerland. Eur J Cancer (1978) 1.13
Chemotherapy studies in primary liver cancer: a prospective randomized clinical trial. Cancer (1978) 1.13
Combination chemotherapy in non-Hodgkin's lymphoma: results of long-term followup. Cancer Treat Rep (1977) 1.12
Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: results of a prospective randomized trial. J Clin Oncol (1991) 1.11
A lesson from the mammography issue. Ann Intern Med (1978) 1.11
Risk of new cancers in patients with Hodgkin's disease. Cancer (1977) 1.11
Lymphoma of the breast. Ann Surg (1981) 1.11
Indomethacin-responsive hypercalcemia in a patient with renal-cell adenocarcinoma. N Engl J Med (1974) 1.10
Pneumocystis carinii pneumonia. Ann Intern Med (1968) 1.10
Persistent immunologic abnormalities in long-term survivors of advanced Hodgkin's disease. Ann Intern Med (1980) 1.10
Characteristics of blast crisis in chronic granulocytic leukemia. Blood (1977) 1.09
Hypercalcemia in chronic granulocytic leukemia. Cancer (1971) 1.08
Clinical trials with 1,3-bis(2-chloroethyl)-1-nitrosourea, NSC-409962. Cancer Res (1965) 1.08
Acetohydroxamate: bacterial urease inhibitor with therapeutic potential in hyperammonaemic states. Nature (1965) 1.07
Vincristine treatment of advanced cancer: a cooperative study of 392 cases. Cancer Res (1973) 1.07
Hodgkin's disease. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med (1967) 1.07